Researchers from Charité – Universitätsmedizin Berlin have gained new insights into the long-term effects of NMDA receptor encephalitis. In this section, first author Dr. Stephan Krohn and senior author Prof. Carsten Finke answer questions about…
- Milestone marks Kupando’s evolution from a research-focused organization to a clinical-stage biopharmaceutical company
- Phase 1 trial evaluates KUP101, a differentiated dual Toll-Like Receptor (TLR) 4/7 agonist designed to harness innate immunity…
- Combining complementary strengths
- A broader range of products for pharmacies from a single source
- A common foundation for reliable supply and growth in Germany and Europe
New vaccine and rapid test approach against the hospital fungus Candida auris.
Researchers find a previously unknown way to selectively activate B cells
G-BA recommends making the Charité treatment concept available to all patients with public health insurance
Nightmares are among the most agonizing symptoms of post-traumatic stress disorder (PTSD) – a condition that can develop after exposure to severe traumatic experiences, such as disasters, serious accidents, acts of violence, or wartime experiences.…
Proceeds support key Phase 3 activities and U.S. expansion following FDA “Study May Proceed” and Fast Track Designation for [⁶⁸Ga]Ga-PentixaFor.
Bringing a new CAR‑T cell therapy from promising results in the lab to critically ill cancer patients is anything but straightforward. A Tagesspiegel podcast featuring, among others, Armin Rehm explores the hurdles that must be overcome along the way…
AbbVie Deutschland is supporting the further development of Nia Health’s digital, AI-supported care offering for people with atopic dermatitis. The approach ranges from documentation in patients’ everyday lives to an “AI Severity Classifier” that…
